Phase Space Research

Credo Technology Group

CRDO · Investment summary · as of 4 August 2026

Priced for an operating path the record does not support

Portfolio decision
No position
Price · 4 August 2026
$218.35
12-month target
$249.09 +14%
Expected return
Not determined
Next decision point
Date not announced

Business type: Cyclical · cyclical or commodity-sensitive

The operating path required by today's price is not achievable on the evidence.

Investment view

At $218.35, CRDO requires a 91% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 71%.

The value rests on an exit multiple of 6.1x, a terminal operating margin of 33% and a 17.0% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

The strongest argument against this view: Customer concentration resolving against Credo.

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?STATE B (cyclical / exogenously driven).
What do we forecast?Revenue growth of 71% demonstrated; a terminal operating margin of 33%; an exit multiple of 6.1x.
What does Street forecast?Not determined — no consensus estimates are joined to this record
Where do we differ?On revenue growth, the difference between what the price requires and what the business has demonstrated is -20.1 percentage points.
What is it worth?Twelve-month target $249.09, +14% from the struck price.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims

Catalysts and falsifiers

Date not announced — no dated event that would resolve the disagreement is on file

Risk and sell discipline

Impairment case

Customer concentration resolving against Credo. The FY2026 10-K states that the top 10 customers were approximately 90% of total revenue and that two customers each exceeded 10%. Product sales are made on a PURCHASE-ORDER basis with no long-term commitments and no minimum-purchase commitments, and the 10-K states customers may cancel, change or delay orders on notice. The named cause of permanent impairment is a single hyperscaler in-sourcing its retimer/AEC connectivity or dual-sourcing to Marvell or Broadcom at the next platform refresh -- an event that removes a double-digit share of revenue with no contractual recourse and no backlog to cushion it.

Estimated probability 18%, against the 18% level at which the position would be resized. It sits within that level.

Fundamental invalidation

Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored

Price-based risk trigger

A daily close below $163.76 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

Trim or exit when the forward expected return falls below the opportunity-cost hurdle, assessed as the point at which the ceiling premium exceeds the sector p90 (48.59x) or the traded EV/NTM EBIT exceeds the 90th percentile of CRDO's own defined history (69.24x). On approach to the $249.09 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default.

Investment criteria

CriteriaStatusInvestment meaning
QualityMetIs the business worth owning under its declared economic type?
ValuationNot metIs the operating path required by today's price achievable?
LiquidityMetCan the intended position be built and exited in the right vehicle?
DownsideMetCustomer concentration resolving against Credo.
MomentumNot determinedDoes price action support or complicate entry timing? Not established on the evidence on file.
CatalystNot determinedIs there a dated event that resolves the disagreement? Not established on the evidence on file.
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The gap between what today's price requires and what the business has demonstrated is -20.1 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: customer concentration resolving against Credo. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $163.76, which forces an immediate review.